BETA2025-10-012025-12-31BETA2025-04-012025-12-31BETA2025-10-012025-12-31in-capmkt:OtherExpenses1MemberBETA2025-04-012025-12-31in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares000000BETANOTLISTEDINE351Y01019BETA DRUGS LIMITEDMain BoardEquity2025-04-012026-03-312026-02-142026-02-10INRLakhsQuarterlyThird quarterSingle segmentPHARMACEUTICAL2026-02-1411:00:002026-02-1413:25:00Not applicable2025-10-012025-12-31UnauditedConsolidated872675000230970008957720003250400000353950001682280004434300043893000174153000791052000104720000010472000021331000-1783000195480000851720000000851720000851720000000101368000108.48.4008.48.41. The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 14th February, 2026. <BR> 2. The company is engaged in single business segment i.e. Pharmaceuticals. <BR> 3. Figures are regrouped/rearranged, wherever considered necessary. <BR> 4. The consolidated financial results include the unaudited financial results of the wholly owned subsidiaries: Adley Formulations Pvt Ltd, Adley Lab Limited and Beta Research Private Limited by management of the Company <BR> 2025-04-012025-12-31UnauditedConsolidated290860800082853000299146100013702960000-1946000049328300011366800012355600048449500025658380004256230000425623000106594000-53080001012860000324337000000032433700003243370000000101368000103232003232Other Expenses174153000Other Expenses484495000000000